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Choroidal neovascularization (CNV) is a well-
documented, major cause of vision loss in age-related
macular degeneration (AMD). It is also a potential
vision-threatening complication of pathologic myopia,
uveitis and traumatic choroidal rupture [1]. CNV
was also reported to be a rare complication associ-
ated with endophthalmitis [2]. Intravitreal injection
of anti-vascular endothelial growth factor (VEGF)
was recently reported to be a safe and effective treat-
ment for CNV secondary to AMD, pathological 
myopia and uveitis [3]. Here, we present a case of
CNV secondary to endogenous endophthalmitis,
which was successfully treated by a single dose of
intravitreal ranibizumab (Lucentis®, Novartis AG,
Basel, Switzerland).
CASE PRESENTATION
A 36-year-old female visited our clinic because of
visual field defects lasting for 1 week. She had suf-
fered from acute lymphocytic leukemia and fungal
pneumonia after chemotherapy. On examination, 
the best-corrected visual acuity was 5/60 in the right
eye and 6/5 in the left eye. The anterior segment 
was silent, except for slightly sluggish light reflex in
the right eye. Fundoscopy showed clear vitreous and
subretinal abscesses in both eyes (Figure 1). Although
the blood culture was negative, systemic antibiotic
and antifungal agents were given empirically because
of the clinical imaging and history. The abscesses
resolved gradually in both eyes (Figure 2). The vision
also recovered to 6/7.5 in both eyes. Unfortunately,
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Choroidal neovascularization is a major cause of visual loss in age-related macular degeneration.
It is also a potential vision-threatening complication of pathologic myopia, uveitis, traumatic
choroidal rupture and, rarely, endophthalmitis. Here, we report a 36-year-old woman with acute
lymphocytic leukemia and fungal pneumonia after chemotherapy who developed endogenous
endophthalmitis in both eyes. The infection was controlled by systemic antibiotic and antifungal
agents. Unfortunately, choroidal neovascularization developed in the right macula 1 month later.
One dose of intravitreal injection of ranibizumab (0.5 mg/0.05 mL) was given, and the macular
exudates resolved rapidly. There was no recurrence or complications during the 10-month 
follow-up.
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recurrent blurred vision developed in the right eye 
1 month later. Ophthalmological examination showed
no recurrence of endophthalmitis but a grayish-
green lesion was found in the right macular center.
Fluorescein angiography showed an early hyperfluo-
rescent lacy net and late leakage in the macular cen-
ter. Optical coherence tomography (OCT) revealed
the presence of CNV and macular edema (Figure 3).
Intravitreal injection of ranibizumab (0.5 mg/0.05 mL)
was given soon after diagnosis, and the macular exu-
dates decreased rapidly. OCT showed resolution of
macular edema and the disappearance of the previ-
ously seen CNV membrane. Best-corrected visual
acuity recovered to 6/7.5. According to the clinical
imaging and OCT findings, the CNV was believed to
have regressed although fluorescein angiography
was not repeated because of her systemic condition.
There was no complication or recurrence during the
10-month follow-up (Figure 4).
DISCUSSION
CNV, if located in the macula, usually causes 
profound central vision loss. It occurs mostly in
AMD, and has been reported as a potential vision-
threatening complication of pathologic myopia,
uveitis and traumatic choroidal rupture [1]. It is also
Figure 1. Fundoscopy showed clear vitreous and subretinal abscesses in both eyes. (A) There were two abscesses in the right eye, one 
in the center of the macula and the other nasolower to the optic disc. (B) The lesion in the left eye was located between the arcade and 
the macula.
Figure 2. Subretinal abscesses resolved gradually, as shown here 1 month after treatment with ranibizumab: (A) right eye; 
(B) left eye.
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rarely reported as a complication associated with
endophthalmitis [2]. In this report, the patient with
leukemia had previously undergone chemotherapy,
which was complicated by fungal pneumonia.
Although no cultures were taken from an ocular
specimen to confirm the diagnosis, endophthalmitis
was diagnosed based on the clinical findings and 
the effects of antibiotic and antifungal treatment.
Ranibizumab for endophthalmitis-related CNV
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Figure 3. (A) Choroidal neovascularization developed at the pre-
vious lesion site of right macular center 1 month later. (B)
Fluorescein angiography showed active leakage. (C) Optical
coherence tomography revealed the presence of choroidal neovas-
cularization and macular edema.
Figure 4. (A) After a single injection of intravitreal
ranibizumab, the macular exudate had almost disappeared at the
2-week follow-up. (B) Two weeks after the treatment with
ranibizumab, optical coherence tomography showed resolution 
of the macular edema. (C) No recurrence was found at the 
10-month follow-up.
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Intravitreal injection of anti-VEGF was recently
reported to be a safe and effective treatment for 
CNV secondary to AMD, pathological myopia and
uveitis [3]. Photodynamic therapy has also been
reported to be useful in arresting the progression of
CNV secondary to Candida endophthalmitis [2].
However, because of the risk for retinal pigment
epithelium damage and the immunocompromised
status of this patient, intravitreal ranibizumab was
used instead [4]. The results of this treatment were
encouraging.
In conclusion, intravitreal ranibizumab can effec-
tively and safely treat CNV secondary to endogenous
endophthalmitis, even in patients with leukemia. This
case also suggests that a single injection of an anti-
VEGF treatment during the very early stages can
eradicate CNV.
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脈絡膜新生血管是年齡相關性黃斑病變視力喪失的主因，它同時也是病態性近視、葡
萄膜炎及外傷性脈絡膜破裂後可能造成視力重大損傷的後遺症，但鮮少發生在眼內炎
後。本病例報告一位 36 歲急性淋巴球性白血病之女性病人於化學治療後發生內因性
眼內炎，在成功以抗生素藥劑治療後又併發右眼黃斑下脈絡膜新生血管，在施予一劑 
ranibizumab (Lucentis，0.5 mg/0.05 mL) 玻璃體腔注射後，黃斑水腫消褪，十
個月的追蹤無復發或併發症發生。
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